ATE256467T1 - Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden - Google Patents

Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden

Info

Publication number
ATE256467T1
ATE256467T1 AT98929022T AT98929022T ATE256467T1 AT E256467 T1 ATE256467 T1 AT E256467T1 AT 98929022 T AT98929022 T AT 98929022T AT 98929022 T AT98929022 T AT 98929022T AT E256467 T1 ATE256467 T1 AT E256467T1
Authority
AT
Austria
Prior art keywords
superoxide radicals
synthetic catalysts
analgesic methods
dismutate superoxide
dismutate
Prior art date
Application number
AT98929022T
Other languages
German (de)
English (en)
Inventor
Daniela Salvemini
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE256467T1 publication Critical patent/ATE256467T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
AT98929022T 1997-06-20 1998-06-15 Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden ATE256467T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5040297P 1997-06-20 1997-06-20
PCT/US1998/012231 WO1998058636A1 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Publications (1)

Publication Number Publication Date
ATE256467T1 true ATE256467T1 (de) 2004-01-15

Family

ID=21965044

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98929022T ATE256467T1 (de) 1997-06-20 1998-06-15 Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden

Country Status (12)

Country Link
US (2) US6180620B1 (https=)
EP (1) EP1001752B1 (https=)
JP (1) JP2002506445A (https=)
AT (1) ATE256467T1 (https=)
AU (1) AU733415B2 (https=)
CA (1) CA2294155A1 (https=)
DE (1) DE69820633T2 (https=)
DK (1) DK1001752T3 (https=)
ES (1) ES2215305T3 (https=)
PT (1) PT1001752E (https=)
WO (1) WO1998058636A1 (https=)
ZA (1) ZA985376B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20060270639A1 (en) * 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
WO1999023097A1 (en) 1997-11-03 1999-05-14 Duke University Substituted porphyrins
ATE312103T1 (de) 1999-01-25 2005-12-15 Nat Jewish Med & Res Center Substituierte porphyrine und deren therapeutische verwendungen
AU5048400A (en) * 1999-05-27 2000-12-18 Monsanto Company Biomaterials modified with superoxide dismutase mimics
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
JP4331939B2 (ja) * 2001-01-05 2009-09-16 メタファー・ファーマシューティカルズ・インコーポレイテッド サイトカイン活性を増強させ、そしてサイトカインの投与に伴う低血圧を治療するための組成物および方法
DE60233317D1 (de) 2001-01-19 2009-09-24 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
EP1353655A2 (en) * 2001-01-26 2003-10-22 Metaphore Pharmaceuticals Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
CA2439971A1 (en) * 2001-03-02 2002-09-12 Metaphore Pharmaceuticals, Inc. Chromatography of metal complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
EP1439842A4 (en) * 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
US20040236519A1 (en) * 2001-06-08 2004-11-25 Marshall Garland R. Libraries of confomationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
CA2451602A1 (en) * 2001-06-26 2003-01-03 Metaphore Pharmaceuticals, Inc. Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease
EP1450824A4 (en) * 2001-11-02 2005-09-28 Elan Corp Plc PHARMACEUTICAL COMPOSITION
WO2003051458A1 (en) * 2001-12-14 2003-06-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US7485721B2 (en) * 2002-06-07 2009-02-03 Duke University Substituted porphyrins
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
CA2397684A1 (en) * 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
EP1551402A4 (en) * 2002-09-23 2009-05-27 Verion Inc PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
CN1717234A (zh) * 2002-12-06 2006-01-04 爱尔康公司 用于治疗眼紊乱和疾病的超氧化物岐化酶模拟物
KR100648618B1 (ko) * 2003-11-19 2006-11-23 주식회사 웰스킨 활성 산소 억제제
MXPA06006187A (es) * 2003-12-11 2006-08-25 Alcon Inc Imitadores de super oxido dismutasa para el tratamiento de dano retinal y de nervio optico.
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006069326A2 (en) * 2004-12-21 2006-06-29 Metaphore Pharmaceuticals, Inc. Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
ES2725023T3 (es) 2006-10-12 2019-09-18 Galera Labs Llc Métodos para el tratamiento de la mucositis oral
US8486928B2 (en) 2007-11-14 2013-07-16 Galera Therapeutics Super-oxide dismutase mimetics
EP2296645B1 (en) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
CN102105146A (zh) 2008-05-23 2011-06-22 国立犹太保健医院 用于治疗与暴露于烷化物质有关的损伤的方法
EP2760874A4 (en) * 2011-09-26 2015-04-08 Galera Therapeutics Llc METHOD FOR THE TREATMENT OF ILLNESSES
RS60558B1 (sr) 2015-08-11 2020-08-31 Galera Labs Llc Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost
KR20180132939A (ko) 2016-05-03 2018-12-12 갈레라 랩스, 엘엘씨 암 치료를 위한 조합 요법
JP7166634B2 (ja) 2016-09-01 2022-11-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法
CA3053779A1 (en) * 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CA3090129A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
US20230071463A1 (en) * 2020-02-13 2023-03-09 Teva Pharmaceuticals International Gmbh Solid state forms of avasopasem manganese and process for preparation thereof
AU2024300676A1 (en) * 2023-07-21 2026-01-29 Board Of Regents Of The University Of Texas System Carcinogenesis reduction with pentaaza macrocyclic ring complex

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US5216021A (en) 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
US4999347A (en) 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
JPS63313581A (ja) * 1987-06-16 1988-12-21 Ube Ind Ltd 修飾ス−パ−オキシドジスムタ−ゼ
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0598753B1 (en) 1991-07-19 1998-03-18 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CN1088086A (zh) * 1992-12-14 1994-06-22 西北大学 一种新型的护肤保健品
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
KR19990087784A (ko) 1996-03-13 1999-12-27 죤 에이치. 뷰센 초과산화물을 불균등화하기 위한 촉매로서 효과적인 질소함유거대고리 리간드의 망간 또는 철착물의 바이오콘쥬게이트

Also Published As

Publication number Publication date
PT1001752E (pt) 2004-05-31
DE69820633D1 (de) 2004-01-29
AU8068598A (en) 1999-01-04
ZA985376B (en) 1999-06-21
AU733415B2 (en) 2001-05-17
JP2002506445A (ja) 2002-02-26
WO1998058636A1 (en) 1998-12-30
CA2294155A1 (en) 1998-12-30
EP1001752A1 (en) 2000-05-24
EP1001752B1 (en) 2003-12-17
US6395725B1 (en) 2002-05-28
US6180620B1 (en) 2001-01-30
DK1001752T3 (da) 2004-04-19
ES2215305T3 (es) 2004-10-01
DE69820633T2 (de) 2004-09-23

Similar Documents

Publication Publication Date Title
ATE256467T1 (de) Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden
DE60035057D1 (de) CD40 Antagonist zur Behandlung von Psoriasis
BE2013C064I2 (https=)
DE59601880D1 (de) Verfahren zur herstellung hydrophiler oder teilweise hydrophiler, anorganischer aerogele
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
FI972205A7 (fi) cGmp-PDE:n estäjiä erektiohäiriön hoidossa
NO983945L (no) Isokinoliner som er nyttige som analgetika
DE69728294D1 (de) Substance p behandlung zur immunostimulierung
ATE323693T1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
BR9402890A (pt) Composição de lubrificante baseado em siloxano no segregador de hidrogênio.
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
IS4628A (is) Frumuröð sem myndar kvalastillandi efni til nota í meðferð gegn sársauka
SE0102858D0 (sv) N-type calcium channel antagonists for the treatment of pain
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
DE60039679D1 (de) Reduktion des molekulargewichts von olefincopolymerisaten
WO2004108069A3 (en) Compositions and methods for promoting neuronal outgrowth
DE69634662D1 (de) Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60105028D1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung
ATE421502T1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
DE59811656D1 (en) Kombinationspräparat aus 2-methylthiazolidin-2,4-dicarbonsäure und paracetamol
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
IL139303A0 (en) Treatment of arthritis and other similar conditions
EE04494B1 (et) 1-oksa-, asa- ja tianaftaleen-2-oon biseetrid fosfolambaani inhibiitoritena

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1001752

Country of ref document: EP

REN Ceased due to non-payment of the annual fee